Novel method to measure serum levels of des‐gamma‐carboxy prothrombin for hepatocellular carcinoma in patients taking warfarin: A preliminary report

Authors:

Abstract
Des‐gamma‐carboxy prothrombin (DCP) is a useful tumor marker for hepatocellular carcinoma (HCC), but its utility is limited in patients taking vitamin K antagonists. We evaluated the NX‐DCP ratio, a newly developed method to measure serum DCP, for its ability to identify DCP elevation induced by HCC in this patient subpopulation. Conventional DCP measurements and the NX‐DCP ratio were compared in patients with and without HCC, all of whom were taking the vitamin K antagonist warfarin. We found no differences in conventional DCP measurements between patients with and without HCC due to warfarin treatment. In contrast, the NX‐DCP ratio was significantly higher in patients with HCC; the NX‐DCP ratio in all patients without HCC was Cancer Sci 2012; 103: 921–925)

This publication has 28 references indexed in Scilit: